The abstract is read at the publisher; the summary is JClub's.
Hypofractionated proton beam therapy (HART) for localized unresectable hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) yields median overall survival of 29.2 months and 20.8 months, respectively.
- Why it matters: Long-term effectiveness and the biology of progression after ablative proton radiation in unresectable primary liver tumors remain unclear, limiting targeted follow-up and combination strategies.
- What they did: In a single-arm, multi-institutional phase II trial of 92 patients (Child-Pugh A/B), investigators delivered HART up to 67.5 GyE in 15 fractions and estimated OS/PFS with Kaplan-Meier; plasma was profiled at baseline and multiple early timepoints.
- The result: Five-year OS was 25.9% for HCC and 12.3% for ICC, with median PFS of 13.8 and 8.4 months; exploratory plasma signatures linked progression to hypoxia and vascular remodeling, and in HCC also inflammation, stromal activation, and hepatic regeneration.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.